Episodes

The $2 Trillion Gene-Editing Market Still in Its Infancy

Episode #69 | September 20, 2018

Episode #69 | September 20, 2018

The $2 Trillion Gene-Editing Market Still in Its Infancy

In This Episode

Amid headlines dominated by the eleventh-hour accusation threatening Brett Kavanaugh’s confirmation to the highest Court in America – check out Porter’s take on the real crime being committed – the Stansberry Investor Hour crew also has its eye on three of the most white-hot profit frontiers of this decade, brought to their attentions courtesy of this week’s guest Matt McCall, editor of Early Stage Investor.
It feels like a week where all of the usual suspects are in the news for dicey reasons. From Elon Musk’s chances of being arrested within the next year as the investigation over his claims to have secured funding for taking Tesla private heats up, to Amazon’s fate at the hands of the BEZOS Act, Porter identifies the real winners – and victims – you’re not seeing in the headlines.
Buck breaks down the political implications of the $200 billion tariff broadside directed at China, and why President Trump is playing a game that gets more dangerous with every round that neither player refuses to blink.
Porter agrees – and mentions how trade war vulnerabilities, combined with storm clouds looming in the corporate bond market, are a great recipe for “true catastrophe.”